
Search results - 6 results
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
the human genome reference sequence of which some may relate to the establishment of the tumour in the patient. A critical point towards a uniform patient management is the assignment of the biological ...
Des patients cancéreux parlent du ngs: Étude de groupe de discussion sur les expériences et les besoins en information
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Wannes Van Hoof; Katrien Moens Source: Sciensano, Brussels, Belgium, p.29 (2019) Keywords: NGS Patient ...
Assessing factors associated with long-term work disability after cancer in Belgium: a population-based cohort study using competing risks analysis with a 7-year follow-up
incidence predictions up to 2025 offers a high value for social security and rehabilitation planning and for ascertaining patients’ perspectives. Health Topics: Cancer Cancer Kanker Service: Centre du ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
particular devices before collection of a cervical sample by a clinician. Sample sets are subsequently analysed in a laboratory accredited for HPV testing. Disease verification for all enrolled patients is ...
Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.
including 34 432 unique patients with PMB and 6358 with endometrial cancer (40 790 women), were analyzed. The pooled prevalence of PMB among women with endometrial cancer was 91% (95% CI, 87%-93%), ...
The use of the permanent sample (eps) to study the returnto- work after cancer. Challenges and opportunities for research
Abstract: INTRODUCTION: The introduction of early cancer detection and the improvement in treatment efficacy have led to a significant increase in the survival and the prevalence of (ex) cancer patients ...